Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-06-18

Novel therapeutic antibodies for multiple myeloma

Article Category

Article available in the following languages:

Genetics of multiple myeloma revealed

Multiple myeloma (MM) is an incurable cancer affecting white blood cells. European researchers have isolated two genes and their proteins that can be targeted using antibodies for potential therapy.

Health icon Health

The 'Novel therapeutic antibodies for multiple myeloma' (MMSC) project aimed to identify candidate oncogenes, genes that can cause cancer, by screening for activity of their proteins. Two genes have been isolated using small hairpin (sh) RNA based screening tools. shRNA molecules can be used to silence target genes and thus assess their function. The proteins from the translated genes can be targeted using monoclonal antibodies or small molecules, many of which are already used in chemotherapy. An attractive candidate, the first gene is part of the Wingless (WNT) pathway, first recognised for its role in carcinogenesis. Mutations of WNT are critical in breast and prostate cancer. This protein is also a receptor tyrosine kinase (RTK). RTKs are often overexpressed in a variety of tumours, leading to enhanced cancer cell survival, and metastasis. Several RTKs are expressed in MM and there is mounting evidence of their relevance in this disease. RTK-targeting therapeutic antibodies and small molecule inhibitors such as Herceptin, Cetuximab, Gleevec, Tarceva and Iressa have successfully induced death in cancerous cells where RTKs are overexpressed. The second gene is also a kinase and part of the Hippo pathway. Inhibition of this kinase using shRNAs was able to trigger cell death in a large range of myeloma cells. Downregulation of this gene in an in vivo setting confirmed that it could be used to unravel mechanisms of cancer cell survival. The results of the MMSC project have provided a firm knowledge platform for the development of targeted drug therapies for MM. Besides advanced research opportunities for pharmaceutical SMEs, MM patients also stand to benefit from improved life quality and outcome.

Keywords

Multiple myeloma, cancer, antibodies, oncogene, small hairpin RNA, Wingless, receptor tyrosine kinase, targeted drug therapy

Discover other articles in the same domain of application